DRAXIS Renews Production Agreement With Pfizer Consumer Healthcare Canada
The new 3-year manufacturing and supply agreement is effective as of January 1, 2005.
MISSISSAUGA, ON – Sept. 1 – DRAXIS Health Inc. (TSX: DAX) (Nasdaq: DRAX) has renewed the production outsourcing agreement between itscontract manufacturing division and Pfizer Canada Inc., Pfizer ConsumerHealthcare division. The new 3-year manufacturing and supply agreement iseffective as of January 1, 2005. DRAXIS Pharma, a division of DRAXIS Specialty Pharmaceuticals Inc., will continue to produce several non-prescriptionproducts as one of a select number of approved suppliers to Pfizer ConsumerHealthcare Canada.
Since early 2000, DRAXIS Pharma has provided production outsourcingservices from its Montreal-based pharmaceutical contract manufacturingfacility for a range of Pfizer Consumer Healthcare products for the Canadianmarketplace, including Polysporin™, Sudafed™, Actifed™ and Zincofax™.
"We have enjoyed a long and mutually-beneficial relationship with PfizerConsumer Healthcare in Canada and we look forward to continuing this specialassociation with them under this renewed contract," said Dr. Martin Barkin,President and Chief Executive Officer of DRAXIS Health.
Draxis Pharma operates a fully integrated 247,000 square-foot cGMPmanufacturing facility in Montreal, Canada. Operations include sterile andnon-sterile processing, lyophilization, packaging and warehousing capabilitiessupported by an experienced quality team. Products manufactured at DraxisPharma are sold in over 100 countries and include sterile injectables andointments, sterile lyophilized products, non-sterile ointments, creams andliquids as well as solid oral dosage forms. Expanded lyophilization capacitycame on line in early 2005.
About DRAXIS Health Inc.
DRAXIS Health, through its wholly owned operating subsidiary, DRAXISSpecialty Pharmaceuticals Inc., provides products in three categories. Sterileproducts include liquid and freeze-dried (lyophilized) injectables plussterile ointments and creams. Non-sterile products are produced as solid oraland semi-solid dosage forms. Radiopharmaceuticals are used for boththerapeutic and diagnostic molecular imaging applications. Pharmaceuticalcontract manufacturing services are provided through the DRAXIS Pharmadivision and radiopharmaceuticals are developed, produced, and sold throughthe DRAXIMAGE division. DRAXIS Specialty Pharmaceuticals Inc. employs over 500staff in its Montreal facility.
For additional information please visit www.draxis.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
